New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human.
About 8% of the adult population is taking angiotensin-converting enzyme (ACE) inhibitors to treat cardiovascular disease including hypertension, myocardial infarction and heart failure. These drugs decrease mortality by up to one-fifth in these patients. We and others have reported previously that...
Main Authors: | Miklós Fagyas, Katalin Úri, Ivetta M Siket, Gábor Á Fülöp, Viktória Csató, Andrea Daragó, Judit Boczán, Emese Bányai, István Elek Szentkirályi, Tamás Miklós Maros, Tamás Szerafin, István Édes, Zoltán Papp, Attila Tóth |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24691203/?tool=EBI |
Similar Items
-
New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition.
by: Miklós Fagyas, et al.
Published: (2014-01-01) -
New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases.
by: Miklós Fagyas, et al.
Published: (2014-01-01) -
New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure.
by: Katalin Úri, et al.
Published: (2014-01-01) -
New evidence of the dual inhibition renin-angiotensin-aldosterone system (RAAS)
by: Xavier Díez
Published: (2010-12-01) -
The renin-angiotensin-aldosterone system (RAAS) – physiology and molecular mechanisms of functioning
by: Monika Chaszczewska-Markowska, et al.
Published: (2016-09-01)